Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

DuPont Launches EverpreX Soybean Herbicide To Protect Crops

ByZacks Investment Research
Published 08/29/2017, 10:41 PM
Updated 07/09/2023, 06:31 AM
DuPont’s (NYSE:DD) Crop Protection business has introduced EverpreX herbicide that offers extended residual control of ALS-, PPO- and/or glyphosate resistant weeds, including waterhemp, Palmer amaranth and other pigweed species.

EverpreX is a valuable solution for weed resistance as it helps safeguard yield potential by minimizing competition for nutrients, moisture and sunlight.

EverpreX provides excellent weed resistance when tank-mixed with glyphosate herbicides, such as DuPont Abundit Edge. It provides a residual control of Palmer amaranth, waterhemp, lambsquarters, nightshade, foxtails and other small-seeded grasses and broadleaf weeds when tank-mixed with other pre- or postemergence herbicides.
EverpreX is compatible and can be easily mixed with many other soybean herbicides. Also, it contains S-metolachlor for residual control via inhibition of shoot- and root-tissue growth soon after weed germination.
The herbicide has the flexibility to be applied 45 days prior to planting and up to 90 days before harvest. It can be used as an early preplant, preplant incorporated, pre-emergence or postemergence herbicide that provides recropping adaptability when rotating from soybeans to other crops.
DuPont has outperformed the industry over a year. The company’s shares have rallied 18.2% compared with the industry’s 17.9% gain during this period.
DuPont kept its positive earnings surprise streak alive with a solid beat in second-quarter 2017. The company recorded adjusted earnings per share of $1.38 in the reported quarter, up 11% from $1.24 a year ago. Results topped the Zacks Consensus Estimate of $1.29. DuPont logged net sales of $7,424 million, up roughly 5% year over year on higher volumes. The figure surpassed the Zacks Consensus Estimate of $$7,260 million.
DuPont is well-positioned to gain from cost-cutting and productivity improvement measures plus product launches. The company has numerous new products in pipeline, expected to create value for customers.
E.I. du Pont de Nemours and Company Price and Consensus

E.I. du Pont de Nemours and Company Price and Consensus | E.I. du Pont de Nemours and Company Quote

Zacks Rank & Stocks to Consider

DuPont currently carries a Zacks Rank #3 (Hold).

Some better-ranked companies in the chemical space include are The Chemours Company (NYSE:CC) , Kronos Worldwide (NYSE:KRO) and Akzo Nobel N.V. (OTC:AKZOY) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Chemours has an expected long-term earnings growth of 15.5%.

Kronos Worldwide has an expected long-term earnings growth of 5%.

Akzo Nobel has an expected long-term earnings growth of 11.1%.

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.

See Stocks Now>>



E.I. du Pont de Nemours and Company (DD): Free Stock Analysis Report

Kronos Worldwide Inc (KRO): Free Stock Analysis Report

Chemours Company (The) (CC): Free Stock Analysis Report

Akzo Nobel NV (AKZOY): Free Stock Analysis Report

Original post

Zacks Investment Research
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.